ASCVD Risk Calculator: Pooled Cohort Equations vs PREVENT

This guide names the current ASCVD risk calculator, the 2026 thresholds, and what to do when a template still says Pooled Cohort Equations (PCE).

Which ASCVD risk calculator should you use now?

Use PREVENT-ASCVD for primary prevention in adults aged 30 to 79. The 2026 ACC/AHA multisociety dyslipidemia guideline recommends it instead of the PCE and replaced the 2018 cholesterol guideline.

The ACC published the guideline online March 13, 2026 (Blumenthal et al., JACC). A search on 2026-10-10 found no newer ACC/AHA dyslipidemia or prevention guideline. Confirm which equation your clinic template uses before you quote a threshold.

PREVENT, published in Circulation by Khan et al., excludes adults with known ASCVD or heart failure. The 2018 guideline calls the PCE the most robust tool for estimating 10-year risk in US adults aged 40 to 75.

What do the 2026 PREVENT thresholds say?

For 10-year PREVENT-ASCVD, 3% to under 5% is borderline, 5% to under 10% is intermediate, and 10% or higher is high risk. LDL-lowering therapy is reasonable for borderline risk and recommended after a clinician-patient discussion for intermediate risk.

The ACC summary describes a calculate, personalize, reclassify sequence:

• Calculate 10- and 30-year PREVENT risk.
• Personalize with enhancers the calculator omits: family history of premature ASCVD, reproductive risk markers, chronic inflammatory disease, and high Lp(a) or hsCRP. The Lp(a) testing guide covers the last one.
• Reclassify, then set goals: LDL-C under 100 mg/dL and non-HDL-C under 130 mg/dL for borderline or intermediate risk, LDL-C under 70 mg/dL and non-HDL-C under 100 mg/dL for high risk.
• Check the 30-year route: 30-year PREVENT-ASCVD risk of 10% or higher is an eligibility route for adults aged 30 to 59.

What if your template still says PCE?

Swap the PCE cutoffs for the PREVENT cutoffs above. PREVENT yields lower average 10-year risk, so old thresholds applied to new numbers would cut statin eligibility sharply, and the 2026 guideline lowers its cutoffs to account for that.

In NHANES adults aged 40 to 75 without ASCVD, mean 10-year risk was 8.0% with the PCE and 4.3% with PREVENT. In the PREVENT validation data, the PCE overestimated risk, with calibration slopes near 0.54 in women and 0.50 in men.

The legacy 2018 scheme sorted PCE risk into borderline (5% to 7.5%) and intermediate (7.5% to 19.9%), refined by risk enhancers, with a moderate-intensity statin at 7.5% or higher after discussion.

Where does coronary artery calcium scoring fit?

Use CAC when the risk estimate leaves the statin question open. The 2026 guideline raised it to Class 1 for risk stratification beyond PREVENT, up from Class 2a.

The ACC journal scan recommends selective noncontrast CAC scanning for men over 40 and women over 45 with borderline or intermediate risk. A score of zero can defer a statin in a low- or intermediate-risk patient with no other cardiovascular comorbidities. Any CAC supports an LDL-C goal under 100 mg/dL, with lower targets for higher scores.

The 2018 guideline said CAC of 0 may justify withholding a statin except in smokers, people with diabetes, and those with strong family history. It favored a statin at 1 to 99 (especially from age 55) and at 100 Agatston units or the 75th percentile and above. Check the 2026 text for updated cutoffs.

Where does this fall short?

Neither tool applies to people with known ASCVD, and both give population-based estimates, so an individual result can differ. The 2026 details here come from ACC summaries because the full guideline text and AHA calculator page returned access errors, so confirm them against the full guideline before changing a protocol. The low-risk cutoff, the 2026 CAC score cutoffs, and the effect of the optional UACR, HbA1c, and SDI inputs remain unconfirmed, and the NHANES analysis applied 2019 eligibility rules. Use the ACC/AHA CV risk calculator (2013 PCE) for legacy comparisons.